Nuvation Bio Inc.

XNYSHealth care

Last traded price · USD

$4.38

−7.40%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:34 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $4.73
Volume: 13,792
Day's high: —
Day's low: —

In brief

Nuvation Bio Inc. is a health care company listed on the New York Stock Exchange, valued at about $1.54B.
Its shares closed at $4.73 on 4 Nov 2026, down 2.1% over the past year.
From India you can buy NUVB in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Nuvation Bio Inc. (NUVB) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole NUVB share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade NUVB options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −3.1% (SPY −1.6%, XLV +13.5%). 3 months: −25.7% (SPY −0.4%, XLV +15.5%). 1 year: −2.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: NUVB, SPY and XLV · as of 4 Nov 2026
9.7 days to cover short interest
63.2M shares were sold short at the 15 Oct 2026 settlement, 18.0% of the 351.1M shares outstanding; covering them would take 9.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
16.9% above its 52-week low
Closed at $4.73 on 4 Nov 2026: 51.5% below the 52-week high of $9.75 (22 Dec 2025) and 16.9% above the low of $4.05 (30 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $4.73 was 14.0% below its 50-day average ($5.50) and 12.0% below its 200-day average ($5.38). It has closed below the 200-day for 31 sessions, since 23 Sep 2026. The 50-day average crossed above the 200-day on 11 Aug 2026, 60 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Volume 1.6× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 8.4M shares was 1.6× the average of the 30 sessions before it (5.4M), as the price rose 0.9%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−3.1%

6 months−6.2%

1 year−2.1%

5 years−50.2%

Newswire

About

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Website

Notable moves

November 19, 2025
+48.96%
March 27, 2024
+37.85%
March 26, 2024
+28.00%

Newswire

About

Website

Notable moves

November 19, 2025
+48.96%
March 27, 2024
+37.85%
March 26, 2024
+28.00%

Nuvation Bio Inc.

XNYSHealth care

Last traded price · USD

$4.38

−7.40%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:34 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $4.73
Volume: 13,792
Day's high: —
Day's low: —

In brief

Nuvation Bio Inc. is a health care company listed on the New York Stock Exchange, valued at about $1.54B.
Its shares closed at $4.73 on 4 Nov 2026, down 2.1% over the past year.
From India you can buy NUVB in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Nuvation Bio Inc. (NUVB) shares from India?

Do I need the price of a whole NUVB share to invest?

How much can I invest in US stocks in a year?

Can I trade NUVB options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −3.1% (SPY −1.6%, XLV +13.5%). 3 months: −25.7% (SPY −0.4%, XLV +15.5%). 1 year: −2.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: NUVB, SPY and XLV · as of 4 Nov 2026
9.7 days to cover short interest
63.2M shares were sold short at the 15 Oct 2026 settlement, 18.0% of the 351.1M shares outstanding; covering them would take 9.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
16.9% above its 52-week low
Closed at $4.73 on 4 Nov 2026: 51.5% below the 52-week high of $9.75 (22 Dec 2025) and 16.9% above the low of $4.05 (30 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $4.73 was 14.0% below its 50-day average ($5.50) and 12.0% below its 200-day average ($5.38). It has closed below the 200-day for 31 sessions, since 23 Sep 2026. The 50-day average crossed above the 200-day on 11 Aug 2026, 60 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Volume 1.6× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 8.4M shares was 1.6× the average of the 30 sessions before it (5.4M), as the price rose 0.9%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−3.1%

6 months−6.2%

1 year−2.1%

5 years−50.2%

Newswire

About

Website

Notable moves

November 19, 2025
+48.96%
March 27, 2024
+37.85%
March 26, 2024
+28.00%

Newswire

About

Website

Notable moves

November 19, 2025
+48.96%
March 27, 2024
+37.85%
March 26, 2024
+28.00%

Nuvation Bio Inc.

Nuvation Bio Inc. in brief

Behind SPY and its sector fund XLV over 1 year

9.7 days to cover short interest

16.9% above its 52-week low

Below its 50- and 200-day averages

Volume 1.6× its 30-session average on 4 Nov 2026

Nuvation Bio Inc.

Nuvation Bio Inc. in brief

Behind SPY and its sector fund XLV over 1 year

9.7 days to cover short interest

16.9% above its 52-week low

Below its 50- and 200-day averages

Volume 1.6× its 30-session average on 4 Nov 2026